Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for RenovoRx, Inc. (RNXT : NSDQ)

• Company Description    RenovoRx Inc. is a biopharmaceutical company. It developed a therapy platform targeting difficult-to-treat tumors. RenovoRx Inc. is headquartered in Silicon Valley, California. Number of Employees: 6

• Price / Volume Information    Yesterday's Closing Price: $1.84 Daily Weekly Monthly 20 Day Moving Average: 35,425 shares Shares Outstanding: 9.07 (millions) Market Capitalization: $16.68 (millions) Beta: 52 Week High: $16.74 52 Week Low: $1.50 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -1.60% 7.74% 12 Week -45.40% -38.64% Year To Date -61.98% -53.56%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 4546 El Camino Real Suite B1 - Los Altos,CA 94022 USA ph: 650-284-4433 fax: 650-397-4433 None http://www.renovorx.com

• General Corporate Information    Officers Shaun R. Bagai - Chief Executive Officer; Director Ramtin Agah - Chairman of the Board of Directors;Chief Medical O Christopher J. Lehman - Chief Financial Officer Laurence J. Marton - Director Una S. Ryan - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 75989R107 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/22 Next Expected EPS Date: 08/15/22 Share - Related Items Shares Outstanding: 9.07 Most Recent Split Date: (:1) Beta: Market Capitalization: $16.68 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.26 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-1.12 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 1.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/15/22

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 1.33 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: -% vs. Previous Quarter: -175.00% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 03/31/22 - -115.27 12/31/21 - -159.68 09/30/21 - - ROA 03/31/22 - -64.69 12/31/21 - -69.06 09/30/21 - - Current Ratio 03/31/22 - 9.92 12/31/21 - 17.36 09/30/21 - 29.06 Quick Ratio 03/31/22 - 9.92 12/31/21 - 17.36 09/30/21 - 29.06 Operating Margin 03/31/22 - - 12/31/21 - - 09/30/21 - - Net Margin 03/31/22 - - 12/31/21 - - 09/30/21 - - Pre-Tax Margin 03/31/22 - - 12/31/21 - - 09/30/21 - - Book Value 03/31/22 - 1.39 12/31/21 - 1.72 09/30/21 - 2.09 Inventory Turnover 03/31/22 - - 12/31/21 - - 09/30/21 - - Debt-to-Equity 03/31/22 - 0.00 12/31/21 - 0.00 09/30/21 - 0.00 Debt-to-Capital 03/31/22 - 0.00 12/31/21 - 0.00 09/30/21 - 0.00

Powered by Zacks Investment Research ©